Full notification file
General informationNotification NumberB/NL/15/002Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority01/06/2015Title of the ProjectThe AGM0001Study: A phase 3 double-blind, randomized, placebo- controlled study to evaluate the safety and efficacy of AGM0001 in subjects with critical limb ischemia.Proposed period of release:01/08/2015 to 01/08/2020Name of the Institute(s) or Company(ies)University Medical Center Utrecht, Utrecht, the Netherlands;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:Other: Purified plasmid DNA (pDNA) drug substance.Identity of the GMO:Not relevant. The plasmid DNA does not have a taxonomic classification.Information relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | pVAX1 | - | - | - | - | - |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known